SCHEMBL1146747

SCHEMBL1146747

CC(C)(C)c1ccc(NC(=O)C2(O)CCN(Cc3ccccc3Cl)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.50
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
PKM P14618 1/20 0.46
TRPV1 Q8NER1 1/20 0.45
P2RY1 P47900 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.43
NPY2R P49146 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43
SLC2A1 P11166 1/20 0.42
KCNJ6 P48051 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1147185 0.88 TRPV1 (0.46) FAAHMAPTRAB9AALDH1A1KDM4E
SCHEMBL1147148 0.87 MEN1 (0.52) MAPTRAB9AALDH1A1KDM4ETRPV1
SCHEMBL1147256 0.87 RAB9A (0.55) FAAHMAPTRAB9AALDH1A1KDM4E
SCHEMBL1146903 0.85 KDM4E (0.48) MAPTALDH1A1KDM4ETRPV1P2RY1
SCHEMBL15387429 0.85 FAAH (0.47) FAAHMAPTLMNARAB9AALDH1A1
SCHEMBL1147361 0.83 EPHX2 (0.45) MAPTLMNARAB9AALDH1A1KDM4E
SCHEMBL1147286 0.82 MAPT (0.54) FAAHMAPTLMNATRPV1P2RY1
SCHEMBL1147214 0.81 HIF1A (0.56) FAAHMAPTRAB9AALDH1A1KDM4E
SCHEMBL1147359 0.80 EPHX2 (0.52) MAPTRAB9AALDH1A1TRPV1KMT2A
SCHEMBL1147337 0.80 FAAH (0.52) FAAHMAPTTRPV1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US claimed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 WO claimed
US-8399676-B2 Piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-8399676-B2 Piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 WO disclosed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES ADRA1D, ADORA1, H1-0 FAAH 2059/4885MAPT 2319/4885LMNA 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.